{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:49:04Z","timestamp":1790938144275,"version":"4.1.0"},"reference-count":153,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The utility of liquid biopsies is well documented in several extracranial and intracranial (brain\/leptomeningeal metastases, gliomas) tumors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The RANO (Response Assessment in Neuro-Oncology) group has set up a multidisciplinary Task Force to critically review the role of blood and cerebrospinal fluid (CSF)\u2013liquid biopsy in CNS lymphomas, with a main focus on primary central nervous system lymphomas (PCNSL).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Several clinical applications are suggested: diagnosis of PCNSL in critical settings (elderly or frail patients, deep locations, and steroid responsiveness), definition of minimal residual disease, early indication of tumor response or relapse following treatments, and prediction of outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Thus far, no clinically validated circulating biomarkers for managing both primary and secondary CNS lymphomas exist. There is need of standardization of biofluid collection, choice of analytes, and type of technique to perform the molecular analysis. The various assays should be evaluated through well-organized central testing within clinical trials.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/neuonc\/noae032","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T18:35:35Z","timestamp":1712774135000},"page":"993-1011","source":"Crossref","is-referenced-by-count":37,"title":["Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review"],"prefix":"10.1093","volume":"26","author":[{"given":"Lakshmi","family":"Nayak","sequence":"first","affiliation":[{"name":"Dana-Farber Cancer Institute, Harvard Medical School , Boston, Massachusetts , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Bettegowda","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Johns Hopkins University School of Medicine , Baltimore, Maryland , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9635-5487","authenticated-orcid":false,"given":"Florian","family":"Scherer","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine, Medical Center\u2014University of Freiburg, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2485-1796","authenticated-orcid":false,"given":"Norbert","family":"Galldiks","sequence":"additional","affiliation":[{"name":"Department of Neurology, University of Cologne, Medical Faculty and University Hospital Cologne, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), and Institute of Neuroscience and Medicine (INM-3), Research Center Juelich , Juelich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manmeet","family":"Ahluwalia","sequence":"additional","affiliation":[{"name":"Rose and Ella Burkhardt Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, Cleveland OH and Miami Cancer Institute, Baptist Health South Florida, International University , Miami, Florida , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Baraniskin","sequence":"additional","affiliation":[{"name":"Department of Hematology, Oncology and Palliative Care, Evangelisches Krankenhaus Hamm , Hamm , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6634-0927","authenticated-orcid":false,"given":"Louisa","family":"von Baumgarten","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Ludwig-Maximilians\u2014University of Munich , Munich , Germany"},{"name":"German Cancer Consortium, Partner Site Munich , Munich , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3830-7142","authenticated-orcid":false,"given":"Jacoline E C","family":"Bromberg","sequence":"additional","affiliation":[{"name":"Erasmus MC University Medical Center Cancer Center , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s J M","family":"Ferreri","sequence":"additional","affiliation":[{"name":"Universit\u00e0 Vita-Salute San Raffaele and IRCCS San Raffaele Scientific Institute , Milano , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Grommes","sequence":"additional","affiliation":[{"name":"Department of Neurology, Memorial Sloan Kettering Cancer Center , New York, New York , USA"},{"name":"Department of Neurology, Weill Cornell Medical College , New York, New York , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kh\u00ea","family":"Hoang-Xuan","sequence":"additional","affiliation":[{"name":"APHP, Department of Neuro-oncology, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re; Sorbonne Universit\u00e9, Paris Brain Institute ICM , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"K\u00fchn","sequence":"additional","affiliation":[{"name":"Department of Medicine I, Faculty of Medicine, Medical Center University of Freiburg, University of Freiburg , Freiburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L","family":"Rubenstein","sequence":"additional","affiliation":[{"name":"UCSF Hematology\/Oncology, Helen Diller Family Comprehensive Cancer Center , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Rud\u00e0","sequence":"additional","affiliation":[{"name":"Division of Neuro-Oncology, Department of Neuroscience \u201cRita Levi Montalcini,\u201d University of Turin , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1748-174X","authenticated-orcid":false,"given":"Michael","family":"Weller","sequence":"additional","affiliation":[{"name":"Department of Neurology, Clinical Neuroscience Center, University Hospital and University of Zurich , Zurich , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery and Division of Neuro-Oncology, University of California , San Francisco, California , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-5127","authenticated-orcid":false,"given":"Martin J","family":"van den Bent","sequence":"additional","affiliation":[{"name":"Erasmus MC Cancer Institute , Rotterdam , The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0774-7700","authenticated-orcid":false,"given":"Patrick Y","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Neuroscience \u201cRita Levi Montalcini,\u201d University of Turin , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9204-7038","authenticated-orcid":false,"given":"Riccardo","family":"Soffietti","sequence":"additional","affiliation":[{"name":"Department of Neuroscience \u201cRita Levi Montalcini,\u201d University of Turin , Turin , Italy"},{"name":"Candiolo Cancer Institute, FPO-IRCCS , Turin , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"issue":"7","key":"2024060308135663700_CIT0001","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia."},{"issue":"11","key":"2024060308135663700_CIT0002","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood."},{"issue":"22","key":"2024060308135663700_CIT0003","doi-asserted-by":"crossref","first-page":"5034","DOI":"10.1200\/JCO.2005.13.524","article-title":"Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma","volume":"23","author":"Abrey","year":"2005","journal-title":"J Clin Oncol."},{"issue":"19","key":"2024060308135663700_CIT0004","first-page":"1","article-title":"Narrative review: biomarkers, a hope towards early diagnosis in primary CNS lymphoma","volume":"5","author":"Steffanoni","year":"2021","journal-title":"Ann Lymphoma"},{"issue":"5","key":"2024060308135663700_CIT0005","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1093\/neuonc\/noz012","article-title":"Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications","volume":"21","author":"Boire","year":"2019","journal-title":"Neuro Oncol"},{"issue":"6","key":"2024060308135663700_CIT0006","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/neuonc\/noac004","article-title":"Liquid biopsy in gliomas: a RANO review and proposals for clinical applications","volume":"24","author":"Soffietti","year":"2022","journal-title":"Neuro Oncol"},{"issue":"6","key":"2024060308135663700_CIT0007","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3174\/ajnr.A2171","article-title":"Central nervous system lymphoma: characteristic findings on traditional and advanced imaging","volume":"32","author":"Haldorsen","year":"2011","journal-title":"AJNR Am J Neuroradiol."},{"issue":"2","key":"2024060308135663700_CIT0008","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0304-3940(02)01367-8","article-title":"Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging","volume":"338","author":"Hartmann","year":"2003","journal-title":"Neurosci Lett."},{"issue":"3","key":"2024060308135663700_CIT0009","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ejrad.2005.12.032","article-title":"Perfusion and diffusion MR imaging in enhancing malignant cerebral tumors","volume":"58","author":"Calli","year":"2006","journal-title":"Eur J Radiol."},{"issue":"3","key":"2024060308135663700_CIT0010","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3174\/ajnr.A0872","article-title":"Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging","volume":"29","author":"Toh","year":"2008","journal-title":"AJNR Am J Neuroradiol."},{"issue":"5","key":"2024060308135663700_CIT0011","first-page":"969","article-title":"Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings","volume":"22","author":"Stadnik","year":"2001","journal-title":"AJNR Am J Neuroradiol."},{"issue":"11","key":"2024060308135663700_CIT0012","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3174\/ajnr.A4867","article-title":"Diffusion-weighted imaging for predicting and monitoring primary central nervous system lymphoma treatment response","volume":"37","author":"Huang","year":"2016","journal-title":"AJNR Am J Neuroradiol."},{"issue":"2","key":"2024060308135663700_CIT0013","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11060-018-2960-z","article-title":"Pretreatment dynamic contrast-enhanced MRI biomarkers correlate with progression-free survival in primary central nervous system lymphoma","volume":"140","author":"Hatzoglou","year":"2018","journal-title":"J Neurooncol."},{"issue":"3","key":"2024060308135663700_CIT0014","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0304-3940(03)00272-6","article-title":"Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy","volume":"342","author":"Harting","year":"2003","journal-title":"Neurosci Lett."},{"issue":"11","key":"2024060308135663700_CIT0015","doi-asserted-by":"crossref","first-page":"8703","DOI":"10.1007\/s00330-021-07845-6","article-title":"Radiomics-based differentiation between glioblastoma and primary central nervous system lymphoma: a comparison of diagnostic performance across different MRI sequences and machine learning techniques","volume":"31","author":"Bathla","year":"2021","journal-title":"Eur Radiol."},{"key":"2024060308135663700_CIT0016","doi-asserted-by":"crossref","first-page":"884173","DOI":"10.3389\/fonc.2022.884173","article-title":"Classifying primary central nervous system lymphoma from glioblastoma using deep learning and radiomics based machine learning approach\u2014a systematic review and meta-analysis","volume":"12","author":"Guha","year":"2022","journal-title":"Front Oncol."},{"issue":"17","key":"2024060308135663700_CIT0017","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.3390\/cancers14174071","article-title":"Role of positron emission tomography in primary central nervous system lymphoma","volume":"14","author":"Rozenblum","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2024060308135663700_CIT0018","doi-asserted-by":"crossref","first-page":"935459","DOI":"10.3389\/fneur.2022.935459","article-title":"Use of 18F-FDG-PET\/CT in differential diagnosis of primary central nervous system lymphoma and high-grade gliomas: a meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Neurol."},{"issue":"5","key":"2024060308135663700_CIT0019","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrneurol.2017.44","article-title":"Advances in neuro-oncology imaging","volume":"13","author":"Langen","year":"2017","journal-title":"Nat Rev Neurol."},{"issue":"10","key":"2024060308135663700_CIT0020","doi-asserted-by":"crossref","first-page":"e241","DOI":"10.1097\/RLU.0b013e318252d1ea","article-title":"(11)C-methionine PET\/CT and MRI of primary central nervous system diffuse large B-cell lymphoma before and after high-dose methotrexate","volume":"37","author":"Jang","year":"2012","journal-title":"Clin Nucl Med."},{"issue":"8","key":"2024060308135663700_CIT0021","doi-asserted-by":"crossref","first-page":"e259","DOI":"10.1097\/RLU.0000000000002154","article-title":"Prognostic significance of interim 11C-methionine PET\/CT in primary central nervous system lymphoma","volume":"43","author":"Ahn","year":"2018","journal-title":"Clin Nucl Med."},{"issue":"5","key":"2024060308135663700_CIT0022","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/jjco\/hyaa010","article-title":"Usefulness of carbon-11-labeled methionine positron-emission tomography for assessing the treatment response of primary central nervous system lymphoma","volume":"50","author":"Miyakita","year":"2020","journal-title":"Jpn J Clin Oncol."},{"issue":"3","key":"2024060308135663700_CIT0023","doi-asserted-by":"crossref","first-page":"266","DOI":"10.4103\/wjnm.WJNM_89_18","article-title":"Utility of FET-PET in detecting high-grade gliomas presenting with equivocal MR imaging features","volume":"18","author":"Puranik","year":"2019","journal-title":"World J Nucl Med"},{"issue":"1","key":"2024060308135663700_CIT0024","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1097\/RLU.0000000000003303","article-title":"High 18F-FDOPA PET uptake in primary central nervous system lymphoma","volume":"46","author":"Salgues","year":"2021","journal-title":"Clin Nucl Med."},{"issue":"12","key":"2024060308135663700_CIT0025","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.2967\/jnumed.120.241703","article-title":"CXCR4-targeted PET imaging of central nervous system B-cell lymphoma","volume":"61","author":"Herhaus","year":"2020","journal-title":"J Nucl Med."},{"issue":"1","key":"2024060308135663700_CIT0026","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/RLU.0000000000003404","article-title":"Assessment of central nervous system lymphoma based on CXCR4 expression in vivo using 68Ga-pentixafor PET\/MRI","volume":"46","author":"Starzer","year":"2021","journal-title":"Clin Nucl Med."},{"issue":"16","key":"2024060308135663700_CIT0027","doi-asserted-by":"crossref","first-page":"4563","DOI":"10.7150\/thno.26754","article-title":"[(18)F]Fludarabine-PET as a promising tool for differentiating CNS lymphoma and glioblastoma: comparative analysis with [(18)F]FDG in human xenograft models","volume":"8","author":"Hovhannisyan","year":"2018","journal-title":"Theranostics"},{"issue":"9","key":"2024060308135663700_CIT0028","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2967\/jnumed.117.206920","article-title":"(18)F-fludarabine PET for lymphoma imaging: first-in-humans study on DLBCL and CLL patients","volume":"59","author":"Chantepie","year":"2018","journal-title":"J Nucl Med."},{"issue":"8","key":"2024060308135663700_CIT0029","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1097\/RLU.0000000000004238","article-title":"First-in-man noninvasive initial diagnostic approach of primary CNS lymphoma versus glioblastoma using PET with 18 F-fludarabine and l-[methyl-11 C]methionine","volume":"47","author":"Postnov","year":"2022","journal-title":"Clin Nucl Med."},{"issue":"3","key":"2024060308135663700_CIT0030","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/ajcp\/110.3.341","article-title":"Enhanced detection of malignant lymphoma in cerebrospinal fluid by multiparameter flow cytometry","volume":"110","author":"Finn","year":"1998","journal-title":"Am J Clin Pathol."},{"issue":"6","key":"2024060308135663700_CIT0031","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/1097-0339(200012)23:6<369::AID-DC1>3.0.CO;2-3","article-title":"Diagnosing lymphoproliferative disorders involving the cerebrospinal fluid: increased sensitivity using flow cytometric analysis","volume":"23","author":"French","year":"2000","journal-title":"Diagn Cytopathol."},{"issue":"2","key":"2024060308135663700_CIT0032","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2004-05-1982","article-title":"High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology","volume":"105","author":"Hegde","year":"2005","journal-title":"Blood."},{"issue":"9","key":"2024060308135663700_CIT0033","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1200\/JCO.2008.17.7089","article-title":"Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin\u2019s lymphoma: improved sensitivity of flow cytometry","volume":"27","author":"Quijano","year":"2009","journal-title":"J Clin Oncol."},{"issue":"4","key":"2024060308135663700_CIT0034","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/neuonc\/nop053","article-title":"Meningeal dissemination in primary CNS lymphoma: diagnosis, treatment, and survival in a large monocenter cohort","volume":"12","author":"Kiewe","year":"2010","journal-title":"Neuro Oncol"},{"issue":"6","key":"2024060308135663700_CIT0035","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1600-0609.2010.01516.x","article-title":"Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology","volume":"85","author":"Schroers","year":"2010","journal-title":"Eur J Haematol."},{"issue":"3","key":"2024060308135663700_CIT0036","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/cyto.b.21001","article-title":"Ten antibodies, six colors, twelve parameters: a multiparameter flow cytometric approach to evaluate leptomeningeal disease in B-cell non-Hodgkin\u2019s lymphomas","volume":"82","author":"Stacchini","year":"2012","journal-title":"Cytometry B Clin Cytom."},{"issue":"16","key":"2024060308135663700_CIT0037","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2012-04-423095","article-title":"Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination","volume":"120","author":"Benevolo","year":"2012","journal-title":"Blood."},{"issue":"1","key":"2024060308135663700_CIT0038","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2006.03.012","article-title":"CSF analysis of IgH gene rearrangement in CNS lymphoma: relationship to the disease course","volume":"247","author":"Ekstein","year":"2006","journal-title":"J Neurol Sci."},{"issue":"3","key":"2024060308135663700_CIT0039","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1212\/WNL.58.3.390","article-title":"CSF evaluation in primary CNS lymphoma patients by PCR of the CDR III IgH genes","volume":"58","author":"Gleissner","year":"2002","journal-title":"Neurology."},{"issue":"14","key":"2024060308135663700_CIT0040","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1212\/01.wnl.0000326958.52546.f5","article-title":"Meningeal dissemination in primary CNS lymphoma: prospective evaluation of 282 patients","volume":"71","author":"Fischer","year":"2008","journal-title":"Neurology."},{"issue":"3","key":"2024060308135663700_CIT0041","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1600-0609.2010.01475.x","article-title":"Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas","volume":"85","author":"Schroers","year":"2010","journal-title":"Eur J Haematol."},{"key":"2024060308135663700_CIT0042","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.cca.2022.06.011","article-title":"Application of cerebrospinal fluid free light chain in diagnosis of primary central nervous system lymphoma and monitoring of associated chemotherapy efficacy","volume":"533","author":"Hu","year":"2022","journal-title":"Clin Chim Acta."},{"issue":"1","key":"2024060308135663700_CIT0043","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1200\/JCO.2007.12.1053","article-title":"Protein biomarker identification in the CSF of patients with CNS lymphoma","volume":"26","author":"Roy","year":"2008","journal-title":"J Clin Oncol."},{"issue":"3","key":"2024060308135663700_CIT0044","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/neuonc\/nor203","article-title":"Cerebrospinal fluid interleukin-10 is a potentially useful biomarker in immunocompetent primary central nervous system lymphoma (PCNSL)","volume":"14","author":"Sasayama","year":"2012","journal-title":"Neuro Oncol"},{"issue":"23","key":"2024060308135663700_CIT0045","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1182\/blood-2013-01-476333","article-title":"CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma","volume":"121","author":"Rubenstein","year":"2013","journal-title":"Blood."},{"issue":"1","key":"2024060308135663700_CIT0046","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s11060-014-1622-z","article-title":"Diagnostic value of interleukin-10 in cerebrospinal fluid for diffuse large B-cell lymphoma of the central nervous system","volume":"121","author":"Sasagawa","year":"2015","journal-title":"J Neurooncol."},{"key":"2024060308135663700_CIT0047","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejca.2016.03.080","article-title":"The CSF IL-10 concentration is an effective diagnostic marker in immunocompetent primary CNS lymphoma and a potential prognostic biomarker in treatment-responsive patients","volume":"61","author":"Nguyen-Them","year":"2016","journal-title":"Eur J Cancer."},{"key":"2024060308135663700_CIT0048","doi-asserted-by":"crossref","first-page":"38671","DOI":"10.1038\/srep38671","article-title":"Cerebrospinal fluid IL-10 and IL-10\/IL-6 as accurate diagnostic biomarkers for primary central nervous system large B-cell lymphoma","volume":"6","author":"Song","year":"2016","journal-title":"Sci Rep."},{"issue":"1","key":"2024060308135663700_CIT0049","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3174\/ajnr.A4450","article-title":"The combined performance of ADC, CSF CXC chemokine ligand 13, and CSF interleukin 10 in the diagnosis of central nervous system lymphoma","volume":"37","author":"Mabray","year":"2016","journal-title":"AJNR Am J Neuroradiol."},{"key":"2024060308135663700_CIT0050","doi-asserted-by":"crossref","first-page":"6261","DOI":"10.2147\/CMAR.S255482","article-title":"High level of IL-10 in cerebrospinal fluid is specific for diagnosis of primary central nervous system lymphoma","volume":"12","author":"Shao","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"8","key":"2024060308135663700_CIT0051","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1007\/s00415-021-10453-5","article-title":"CSF interleukin 6 is a useful marker to distinguish pseudotumoral CNS inflammatory diseases from primary CNS lymphoma","volume":"268","author":"Ungureanu","year":"2021","journal-title":"J Neurol."},{"issue":"1","key":"2024060308135663700_CIT0052","first-page":"2","article-title":"Clinical significance of interleukin-10 concentration in the cerebrospinal fluid of patients with primary central nervous system lymphoma","volume":"21","author":"Geng","year":"2021","journal-title":"Oncol Lett"},{"issue":"3","key":"2024060308135663700_CIT0053","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/09273948.2021.1878233","article-title":"Consensus recommendations for the diagnosis of vitreoretinal lymphoma","volume":"29","author":"Carbonell","year":"2021","journal-title":"Ocul Immunol Inflamm."},{"issue":"1","key":"2024060308135663700_CIT0054","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s11060-016-2162-5","article-title":"Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma","volume":"129","author":"Strehlow","year":"2016","journal-title":"J Neurooncol."},{"issue":"12","key":"2024060308135663700_CIT0055","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/neuonc\/nox097","article-title":"Soluble TACI and soluble BCMA as biomarkers in primary central nervous system lymphoma","volume":"19","author":"Thaler","year":"2017","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024060308135663700_CIT0056","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13045-019-0796-4","article-title":"APRIL and BAFF: novel biomarkers for central nervous system lymphoma","volume":"12","author":"Mulazzani","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2024060308135663700_CIT0057","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1111\/j.1600-065X.2012.01105.x","article-title":"Pathogenetic importance and therapeutic implications of NF-\u03baB in lymphoid malignancies","volume":"246","author":"Lim","year":"2012","journal-title":"Immunol Rev."},{"issue":"6","key":"2024060308135663700_CIT0058","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s00401-011-0891-2","article-title":"Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma","volume":"122","author":"Montesinos-Rongen","year":"2011","journal-title":"Acta Neuropathol."},{"issue":"2","key":"2024060308135663700_CIT0059","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/bjh.13293","article-title":"Absence of CXCR4 mutations but high incidence of double mutant in CD79A\/B and MYD88 in primary central nervous system lymphoma","volume":"170","author":"Poulain","year":"2015","journal-title":"Br J Haematol."},{"issue":"6","key":"2024060308135663700_CIT0060","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1007\/s00401-016-1536-2","article-title":"Genomic characterization of primary central nervous system lymphoma","volume":"131","author":"Fukumura","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2024060308135663700_CIT0061","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1111\/nan.12259","article-title":"Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas","volume":"42","author":"Nakamura","year":"2016","journal-title":"Neuropathol Appl Neurobiol."},{"issue":"9","key":"2024060308135663700_CIT0062","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-17-0613","article-title":"Ibrutinib unmasks critical role of bruton tyrosine kinase in primary CNS lymphoma","volume":"7","author":"Grommes","year":"2017","journal-title":"Cancer Discov"},{"issue":"3","key":"2024060308135663700_CIT0063","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/bjh.17357","article-title":"MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study","volume":"193","author":"Ferreri","year":"2021","journal-title":"Br J Haematol."},{"issue":"13","key":"2024060308135663700_CIT0064","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1182\/blood-2012-09-457101","article-title":"Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom\u2019s macroglobulinemia and related lymphoid neoplasms","volume":"121","author":"Varettoni","year":"2013","journal-title":"Blood."},{"issue":"1","key":"2024060308135663700_CIT0065","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/cas.13450","article-title":"Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma","volume":"109","author":"Hattori","year":"2018","journal-title":"Cancer Sci."},{"key":"2024060308135663700_CIT0066","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.critrevonc.2018.05.010","article-title":"Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: review of literature and future opportunities","volume":"127","author":"Hiemcke-Jiwa","year":"2018","journal-title":"Crit Rev Oncol Hematol."},{"issue":"1","key":"2024060308135663700_CIT0067","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s40478-019-0692-8","article-title":"Tumor cell-free DNA detection in CSF for primary CNS lymphoma diagnosis","volume":"7","author":"Rimelen","year":"2019","journal-title":"Acta Neuropathol Commun"},{"issue":"3","key":"2024060308135663700_CIT0068","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.18.00308","article-title":"High detection rate of MYD88 mutations in cerebrospinal fluid from patients with CNS lymphomas","volume":"3","author":"Watanabe","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"10","key":"2024060308135663700_CIT0069","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/j.jmoldx.2020.07.002","article-title":"Analysis of driver mutational hot spots in blood-derived cell-free DNA of patients with primary central nervous system lymphoma obtained before intracerebral biopsy","volume":"22","author":"Montesinos-Rongen","year":"2020","journal-title":"J Mol Diagn."},{"issue":"5","key":"2024060308135663700_CIT0070","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1182\/blood.2020010137","article-title":"A rapid genotyping panel for detection of primary central nervous system lymphoma","volume":"138","author":"Gupta","year":"2021","journal-title":"Blood."},{"issue":"11","key":"2024060308135663700_CIT0071","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1111\/cas.15133","article-title":"Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma","volume":"112","author":"Yamagishi","year":"2021","journal-title":"Cancer Sci."},{"issue":"22","key":"2024060308135663700_CIT0072","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1002\/cam4.3499","article-title":"Clinical outcomes of newly diagnosed primary CNS lymphoma treated with ibrutinib-based combination therapy: a real-world experience of off-label ibrutinib use","volume":"9","author":"Chen","year":"2020","journal-title":"Cancer Med"},{"issue":"6","key":"2024060308135663700_CIT0073","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1111\/cas.15762","article-title":"Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma","volume":"114","author":"Yamaguchi","year":"2023","journal-title":"Cancer Sci."},{"issue":"6","key":"2024060308135663700_CIT0074","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/bjh.18758","article-title":"Combining MYD88 L265P mutation detection and clonality determination on CSF cellular and cell-free DNA improves diagnosis of primary CNS lymphoma","volume":"201","author":"Bravetti","year":"2023","journal-title":"Br J Haematol."},{"issue":"1","key":"2024060308135663700_CIT0075","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1182\/blood-2015-01-620518","article-title":"High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates","volume":"126","author":"Bonzheim","year":"2015","journal-title":"Blood."},{"issue":"4","key":"2024060308135663700_CIT0076","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1097\/IAE.0000000000002319","article-title":"MYD88 L265P mutation detection in the aqueous humor of patients with vitreoretinal lymphoma","volume":"39","author":"Miserocchi","year":"2019","journal-title":"Retina."},{"issue":"29","key":"2024060308135663700_CIT0077","doi-asserted-by":"crossref","first-page":"48157","DOI":"10.18632\/oncotarget.18325","article-title":"Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma","volume":"8","author":"Fontanilles","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"2024060308135663700_CIT0078","doi-asserted-by":"crossref","first-page":"597","DOI":"10.4143\/crt.2021.752","article-title":"Plasma circulating tumor DNA in patients with primary central nervous system lymphoma","volume":"54","author":"Yoon","year":"2022","journal-title":"Cancer Res Treat"},{"issue":"9","key":"2024060308135663700_CIT0079","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.22.00826","article-title":"Circulating tumor DNA profiling for detection, risk stratification, and classification of brain lymphomas","volume":"41","author":"Mutter","year":"2023","journal-title":"J Clin Oncol."},{"issue":"5","key":"2024060308135663700_CIT0080","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/blood-2018-09-875732","article-title":"Phase 1b trial of an ibrutinib-based combination therapy in recurrent\/refractory CNS lymphoma","volume":"133","author":"Grommes","year":"2019","journal-title":"Blood."},{"issue":"11","key":"2024060308135663700_CIT0081","doi-asserted-by":"crossref","first-page":"3140","DOI":"10.1182\/blood-2010-09-308684","article-title":"Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system","volume":"117","author":"Baraniskin","year":"2011","journal-title":"Blood."},{"issue":"2","key":"2024060308135663700_CIT0082","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s11060-012-0908-2","article-title":"MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma","volume":"109","author":"Baraniskin","year":"2012","journal-title":"J Neurooncol."},{"issue":"11","key":"2024060308135663700_CIT0083","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/cancers11111647","article-title":"Tumor and cerebrospinal fluid microRNAs in primary central nervous system lymphomas","volume":"11","author":"Zajdel","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2024060308135663700_CIT0084","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10072-013-1491-9","article-title":"Serum miR-21 is a diagnostic and prognostic marker of primary central nervous system lymphoma","volume":"35","author":"Mao","year":"2014","journal-title":"Neurol Sci."},{"issue":"2","key":"2024060308135663700_CIT0085","doi-asserted-by":"crossref","first-page":"e0229577","DOI":"10.1371\/journal.pone.0229577","article-title":"miR-101, miR-548b, miR-554, and miR-1202 are reliable prognosis predictors of the miRNAs associated with cancer immunity in primary central nervous system lymphoma","volume":"15","author":"Takashima","year":"2020","journal-title":"PLoS One."},{"key":"2024060308135663700_CIT0086","doi-asserted-by":"crossref","first-page":"5052609","DOI":"10.1155\/2022\/5052609","article-title":"Identification of serum miRNAs as effective diagnostic biomarkers for distinguishing primary central nervous system lymphoma from glioma","volume":"2022","author":"Si","year":"2022","journal-title":"J Immunol Res"},{"issue":"17","key":"2024060308135663700_CIT0087","first-page":"6335","article-title":"Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas","volume":"61","author":"Nakamura","year":"2001","journal-title":"Cancer Res."},{"issue":"1","key":"2024060308135663700_CIT0088","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/1471-2407-9-455","article-title":"Array-based DNA methylation profiling of primary lymphomas of the central nervous system","volume":"9","author":"Richter","year":"2009","journal-title":"BMC Cancer"},{"issue":"6","key":"2024060308135663700_CIT0089","doi-asserted-by":"crossref","first-page":"e727","DOI":"10.1097\/HS9.0000000000000727","article-title":"Controversies in the interpretation of liquid biopsy data in lymphoma","volume":"6","author":"Pirosa","year":"2022","journal-title":"HemaSphere"},{"issue":"10","key":"2024060308135663700_CIT0090","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1002\/ijc.22124","article-title":"Epigenetic silencing of multiple genes in primary CNS lymphoma","volume":"119","author":"Chu","year":"2006","journal-title":"Int J Cancer."},{"issue":"5","key":"2024060308135663700_CIT0091","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2141.2004.05109.x","article-title":"Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas","volume":"126","author":"Ferreri","year":"2004","journal-title":"Br J Haematol."},{"issue":"2","key":"2024060308135663700_CIT0092","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/j.1750-3639.1998.tb00152.x","article-title":"Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL","volume":"8","author":"Cobbers","year":"1998","journal-title":"Brain Pathol."},{"issue":"1","key":"2024060308135663700_CIT0093","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0165-4608(02)00799-9","article-title":"CpG island methylation of tumor-related genes in three primary central nervous system lymphomas in immunocompetent patients","volume":"142","author":"Gonzalez-Gomez","year":"2003","journal-title":"Cancer Genet Cytogenet."},{"issue":"1","key":"2024060308135663700_CIT0094","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s13148-021-01091-9","article-title":"Methylated markers accurately distinguish primary central nervous system lymphomas (PCNSL) from other CNS tumors","volume":"13","author":"Downs","year":"2021","journal-title":"Clin Epigenetics"},{"issue":"4","key":"2024060308135663700_CIT0095","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1586\/erm.10.17","article-title":"DNA methylation as a universal biomarker","volume":"10","author":"Levenson","year":"2010","journal-title":"Expert Rev Mol Diagn."},{"key":"2024060308135663700_CIT0096","doi-asserted-by":"crossref","first-page":"11115","DOI":"10.1038\/ncomms11115","article-title":"Genetic and environmental influences interact with age and sex in shaping the human methylome","volume":"7","author":"van Dongen","year":"2016","journal-title":"Nat Commun."},{"issue":"3","key":"2024060308135663700_CIT0097","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.ccell.2017.08.006","article-title":"Chronic cigarette smoke-induced epigenomic changes precede sensitization of bronchial epithelial cells to single-step transformation by KRAS mutations","volume":"32","author":"Vaz","year":"2017","journal-title":"Cancer Cell"},{"issue":"1","key":"2024060308135663700_CIT0098","doi-asserted-by":"crossref","first-page":"12564","DOI":"10.1038\/s41598-020-69432-x","article-title":"Evaluating the quantity, quality and size distribution of cell-free DNA by multiplex droplet digital PCR","volume":"10","author":"Alcaide","year":"2020","journal-title":"Sci Rep."},{"issue":"10","key":"2024060308135663700_CIT0099","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1038\/nprot.2013.118","article-title":"Tagmentation-based whole-genome bisulfite sequencing","volume":"8","author":"Wang","year":"2013","journal-title":"Nat Protocols."},{"issue":"3","key":"2024060308135663700_CIT0100","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ymeth.2010.06.012","article-title":"Whole-genome DNA methylation profiling using MethylCap-seq","volume":"52","author":"Brinkman","year":"2010","journal-title":"Methods."},{"issue":"7303","key":"2024060308135663700_CIT0101","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nature09165","article-title":"Conserved role of intragenic DNA methylation in regulating alternative promoters","volume":"466","author":"Maunakea","year":"2010","journal-title":"Nature."},{"issue":"4","key":"2024060308135663700_CIT0102","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/nprot.2010.190","article-title":"Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling","volume":"6","author":"Gu","year":"2011","journal-title":"Nat Protocols."},{"issue":"10","key":"2024060308135663700_CIT0103","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1038\/s41596-019-0202-2","article-title":"Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA","volume":"14","author":"Shen","year":"2019","journal-title":"Nat Protocols."},{"issue":"8","key":"2024060308135663700_CIT0104","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1093\/neuonc\/noac264","article-title":"Cerebrospinal fluid methylome-based liquid biopsies for accurate malignant brain neoplasm classification","volume":"25","author":"Zuccato","year":"2023","journal-title":"Neuro Oncol"},{"issue":"2","key":"2024060308135663700_CIT0105","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/bjh.18539","article-title":"Management of secondary central nervous system lymphoma","volume":"200","author":"Cwynarski","year":"2023","journal-title":"Br J Haematol."},{"issue":"10","key":"2024060308135663700_CIT0106","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1093\/annonc\/mdx353","article-title":"Central nervous system relapse of diffuse large B-cell lymphoma in the rituximab era: results of the UK NCRI R-CHOP-14 versus 21 trial","volume":"28","author":"Gleeson","year":"2017","journal-title":"Ann Oncol."},{"issue":"2","key":"2024060308135663700_CIT0107","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/bjh.16064","article-title":"Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance","volume":"187","author":"Wight","year":"2019","journal-title":"Br J Haematol."},{"issue":"5","key":"2024060308135663700_CIT0108","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3324\/haematol.2012.070839","article-title":"Central nervous system recurrence of systemic lymphoma in the era of stem cell transplantation\u2014an International Primary Central Nervous System Lymphoma Study Group project","volume":"98","author":"Bromberg","year":"2013","journal-title":"Haematologica."},{"issue":"9","key":"2024060308135663700_CIT0109","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1182\/blood-2014-10-604561","article-title":"R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma","volume":"125","author":"Omuro","year":"2015","journal-title":"Blood."},{"issue":"10","key":"2024060308135663700_CIT0110","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1002\/dc.23539","article-title":"Accuracy of flow cytometry and cytomorphology for the diagnosis of meningeal involvement in lymphoid neoplasms: a systematic review","volume":"44","author":"Canovi","year":"2016","journal-title":"Diagn Cytopathol."},{"issue":"10","key":"2024060308135663700_CIT0111","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1200\/JCO.18.00306","article-title":"Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the intergroup ANOCEF-GOELAMS randomized phase II PRECIS study","volume":"37","author":"Houillier","year":"2019","journal-title":"J Clin Oncol."},{"issue":"11","key":"2024060308135663700_CIT0112","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.3390\/cancers13112665","article-title":"Liquid biopsy and other non-invasive diagnostic measures in PCNSL","volume":"13","author":"Baraniskin","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2024060308135663700_CIT0113","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.3390\/cancers14092305","article-title":"Circulating microRNAs in cerebrospinal fluid and plasma: sensitive tool for detection of secondary CNS involvement, monitoring of therapy and prediction of CNS relapse in aggressive B-NHL lymphomas","volume":"14","author":"Krsmanovic","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"21","key":"2024060308135663700_CIT0114","doi-asserted-by":"crossref","first-page":"9628","DOI":"10.1158\/0008-5472.CAN-05-2352","article-title":"A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation","volume":"65","author":"Hayashita","year":"2005","journal-title":"Cancer Res."},{"issue":"3","key":"2024060308135663700_CIT0115","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1111\/j.1750-3639.2009.00328.x","article-title":"Identification and functional characterization of microRNAs involved in the malignant progression of gliomas","volume":"20","author":"Malzkorn","year":"2010","journal-title":"Brain Pathol."},{"issue":"8","key":"2024060308135663700_CIT0116","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1038\/onc.2011.296","article-title":"Identification of oncogenic microRNA-17-92\/ZBTB4\/specificity protein axis in breast cancer","volume":"31","author":"Kim","year":"2012","journal-title":"Oncogene."},{"issue":"14","key":"2024060308135663700_CIT0117","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1080\/10428194.2019.1639169","article-title":"Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma","volume":"60","author":"Watanabe","year":"2019","journal-title":"Leuk Lymphoma."},{"issue":"2","key":"2024060308135663700_CIT0118","doi-asserted-by":"crossref","first-page":"513","DOI":"10.3324\/haematol.2019.241208","article-title":"Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas","volume":"106","author":"Bobillo","year":"2021","journal-title":"Haematologica."},{"issue":"24","key":"2024060308135663700_CIT0119","doi-asserted-by":"crossref","first-page":"5525","DOI":"10.1182\/bloodadvances.2021004512","article-title":"Detection of clonotypic DNA in the cerebrospinal fluid as a marker of central nervous system invasion in lymphoma","volume":"5","author":"Olszewski","year":"2021","journal-title":"Blood Adv."},{"issue":"7802","key":"2024060308135663700_CIT0120","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41586-020-2140-0","article-title":"Integrating genomic features for non-invasive early lung cancer detection","volume":"580","author":"Chabon","year":"2020","journal-title":"Nature."},{"issue":"8","key":"2024060308135663700_CIT0121","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.3390\/cancers12082277","article-title":"Clonal hematopoiesis in liquid biopsy: from biological noise to valuable clinical implications","volume":"12","author":"Chan","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2024060308135663700_CIT0122","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/1471-2407-7-185","article-title":"Assessment of free light chains in the cerebrospinal fluid of patients with lymphomatous meningitis\u2014a pilot study","volume":"7","author":"Hildebrandt","year":"2007","journal-title":"BMC Cancer"},{"issue":"9","key":"2024060308135663700_CIT0123","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1001\/archneur.1987.00520210017012","article-title":"Cerebrospinal fluid immunoglobulins and beta 2-microglobulin in lymphoproliferative and other neoplastic diseases of the central nervous system","volume":"44","author":"Ernerudh","year":"1987","journal-title":"Arch Neurol."},{"issue":"12","key":"2024060308135663700_CIT0124","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2013-11-537993","article-title":"Contribution of cerebrospinal fluid sCD19 levels to the detection of CNS lymphoma and its impact on disease outcome","volume":"123","author":"Mu\u00f1iz","year":"2014","journal-title":"Blood."},{"issue":"5","key":"2024060308135663700_CIT0125","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1182\/blood.V87.5.1985.1985","article-title":"Elevation of cerebrospinal fluid soluble CD27 levels in patients with meningeal localization of lymphoid malignancies","volume":"87","author":"Kersten","year":"1996","journal-title":"Blood."},{"issue":"5","key":"2024060308135663700_CIT0126","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/annonc\/mdp432","article-title":"Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy","volume":"21","author":"Villa","year":"2010","journal-title":"Ann Oncol."},{"issue":"26","key":"2024060308135663700_CIT0127","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","article-title":"CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-Cell lymphoma treated with R-CHOP","volume":"34","author":"Schmitz","year":"2016","journal-title":"J Clin Oncol."},{"issue":"1","key":"2024060308135663700_CIT0128","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1182\/asheducation-2017.1.578","article-title":"Secondary CNS relapse in diffuse large B-cell lymphoma: defining high-risk patients and optimization of prophylaxis strategies","volume":"2017","author":"Savage","year":"2017","journal-title":"Hematol Am Soc Hematol Educ Program."},{"issue":"18","key":"2024060308135663700_CIT0129","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood-2015-10-676700","article-title":"Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL","volume":"127","author":"Savage","year":"2016","journal-title":"Blood."},{"issue":"5","key":"2024060308135663700_CIT0130","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med."},{"issue":"15","key":"2024060308135663700_CIT0131","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med."},{"issue":"9","key":"2024060308135663700_CIT0132","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1182\/blood-2018-07-862862","article-title":"Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL","volume":"133","author":"Klanova","year":"2019","journal-title":"Blood."},{"issue":"8","key":"2024060308135663700_CIT0133","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020007236","article-title":"Genomic subtypes may predict the risk of central nervous system recurrence in diffuse large B-cell lymphoma","volume":"137","author":"Ollila","year":"2021","journal-title":"Blood."},{"issue":"7","key":"2024060308135663700_CIT0134","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ajh.26181","article-title":"Ineffectiveness of high-dose methotrexate for prevention of CNS relapse in diffuse large B-cell lymphoma","volume":"96","author":"Puckrin","year":"2021","journal-title":"Am J Hematol."},{"issue":"3","key":"2024060308135663700_CIT0135","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1182\/blood.2021012888","article-title":"Single-route CNS prophylaxis for aggressive non-Hodgkin lymphomas: real-world outcomes from 21 US academic institutions","volume":"139","author":"Orellana-Noia","year":"2022","journal-title":"Blood."},{"issue":"16","key":"2024060308135663700_CIT0136","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2021014506","article-title":"Timing of high-dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1384 patients","volume":"139","author":"Wilson","year":"2022","journal-title":"Blood."},{"issue":"6","key":"2024060308135663700_CIT0137","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00401-012-1064-7","article-title":"Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma","volume":"124","author":"Montesinos-Rongen","year":"2012","journal-title":"Acta Neuropathol."},{"issue":"3","key":"2024060308135663700_CIT0138","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/neuonc\/noy193","article-title":"Introduction of novel agents in the treatment of primary CNS lymphoma","volume":"21","author":"Grommes","year":"2019","journal-title":"Neuro Oncol"},{"issue":"17","key":"2024060308135663700_CIT0139","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1158\/1078-0432.CCR-14-2116","article-title":"Genome-wide analysis uncovers novel recurrent alterations in primary central nervous system lymphomas","volume":"21","author":"Braggio","year":"2015","journal-title":"Clin Cancer Res."},{"issue":"7","key":"2024060308135663700_CIT0140","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood."},{"issue":"2","key":"2024060308135663700_CIT0141","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.annonc.2022.11.002","article-title":"Molecular and clinical diversity in primary central nervous system lymphoma","volume":"34","author":"Hern\u00e1ndez-Verdin","year":"2023","journal-title":"Ann Oncol."},{"issue":"9","key":"2024060308135663700_CIT0142","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1182\/blood-2005-03-0897","article-title":"Gene expression and angiotropism in primary CNS lymphoma","volume":"107","author":"Rubenstein","year":"2006","journal-title":"Blood."},{"issue":"10","key":"2024060308135663700_CIT0143","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1093\/neuonc\/nor107","article-title":"Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas","volume":"13","author":"Fischer","year":"2011","journal-title":"Neuro Oncol"},{"issue":"3","key":"2024060308135663700_CIT0144","doi-asserted-by":"crossref","first-page":"145","DOI":"10.3960\/jslrt.56.145","article-title":"TET2 mutation in diffuse large B-cell lymphoma","volume":"56","author":"Kubuki","year":"2017","journal-title":"J Clin Exp Hematop."},{"issue":"1","key":"2024060308135663700_CIT0145","first-page":"vdac181","article-title":"Cerebrospinal fluid metabolic markers predict prognosis behavior of primary central nervous system lymphoma with high-dose methotrexate-based chemotherapeutic treatment","volume":"5","author":"Zhou","year":"2022","journal-title":"Neurooncol Adv"},{"issue":"13","key":"2024060308135663700_CIT0146","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1182\/bloodadvances.2017014845","article-title":"Phase 1 investigation of lenalidomide\/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma","volume":"2","author":"Rubenstein","year":"2018","journal-title":"Blood Adv."},{"issue":"1","key":"2024060308135663700_CIT0147","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/bjh.18598","article-title":"Cerebrospinal fluid soluble programmed death-ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma","volume":"201","author":"Cheng","year":"2023","journal-title":"Br J Haematol."},{"issue":"36","key":"2024060308135663700_CIT0148","doi-asserted-by":"crossref","first-page":"14508","DOI":"10.1073\/pnas.1208715109","article-title":"Detection of ultra-rare mutations by next-generation sequencing","volume":"109","author":"Schmitt","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"11","key":"2024060308135663700_CIT0149","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1038\/nprot.2014.170","article-title":"Detecting ultralow-frequency mutations by Duplex Sequencing","volume":"9","author":"Kennedy","year":"2014","journal-title":"Nat Protoc"},{"issue":"5","key":"2024060308135663700_CIT0150","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/nbt.3520","article-title":"Integrated digital error suppression for improved detection of circulating tumor DNA","volume":"34","author":"Newman","year":"2016","journal-title":"Nat Biotechnol."},{"issue":"12","key":"2024060308135663700_CIT0151","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","article-title":"Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA","volume":"39","author":"Kurtz","year":"2021","journal-title":"Nat Biotechnol."},{"issue":"1","key":"2024060308135663700_CIT0152","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1093\/neuonc\/noac196","article-title":"European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)","volume":"25","author":"Hoang-Xuan","year":"2023","journal-title":"Neuro Oncol"},{"issue":"1","key":"2024060308135663700_CIT0153","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s11060-021-03837-0","article-title":"Biomarkers and focused ultrasound: the future of liquid biopsy for brain tumor patients","volume":"156","author":"Rincon-Torroella","year":"2022","journal-title":"J Neurooncol."}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/advance-article-pdf\/doi\/10.1093\/neuonc\/noae032\/57904745\/noae032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/6\/993\/58057525\/noae032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/26\/6\/993\/58057525\/noae032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T16:45:02Z","timestamp":1717433102000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article\/26\/6\/993\/7643770"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,10]]},"references-count":153,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,4,10]]},"published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/neuonc\/noae032","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6,1]]},"published":{"date-parts":[[2024,4,10]]}}}